EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate By Ogkologos - February 20, 2026 388 0 Facebook Twitter Google+ Pinterest WhatsApp New combination concerns a combination with ADT for the treatment of adult patients with mHSPC and BRCA1/2 mutations Source RELATED ARTICLESMORE FROM AUTHOR Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL MOST POPULAR How to Discuss Your Goals of Care With Your Cancer Care... October 17, 2023 Marginal Benefit in Overall and Progression-Free Survival from New Anticancer Drugs August 12, 2022 Our new strategy to make discoveries, drive progress, and bring hope March 17, 2022 Associations Between Genomic Features and Response to Neoadjuvant Treatment in a... August 30, 2022 Load more HOT NEWS Hormone Therapy Can Put Cancer Cells Into Sleep Mode And Cause... Sacituzumab Govitecan Does Not Demonstrate a Statistically Significant OS Improvement in... Intensive Program Helps People Being Screened for Lung Cancer Quit Smoking Boy Asks Mom Fighting Cancer To Take Off Her Turban So...
